Back to Agenda
Session 8: ABSTRACT SESSION
Session Chair(s)
Lisa Melanie Harinstein, PHARMD
Team Leader, Division of Pharmacovigilance, FDA, FDA, United States
For the first time at the DIA Pharmacovigilance and Risk Management Strategies Conference, this new session will feature four presentations selected from an abstract submission process. This session will explore the innovative use of pharmacoepidemiology studies, real world evidence, social media, and signal management tools in pharmacovigilance.
Speaker(s)
Ruben Ayzin Rosoky, MD, PHD
Global Program Safety Lead, Novartis, France
Michael Forstner, PHD, MPH, MSC
Managing Director, Head of Pharmacoepidemiology Practice, Mesa Laubela-Consulting, Switzerland
Jennifer B Hannan, MS
Director, Pharmacovigilance Business Liaison, Merck & Co., Inc., United States
Sanjeev Miglani, MD
Founder and Director, AWINSA Life Sciences, United States
Irene Cosmatos, MS
Senior Director, Epidemiology & Real-World Evidence, UBC, United States
Have an account?